Sorrento Therapeutics Inc logo

Sorrento Therapeutics Inc

1
OTCPK:SRNEQ (USA)  
$ 0.01 0 (0%) 07:09 PM EST
At Loss
Enterprise V:
$ 131.38M
Volume:
199.23K
Avg Vol (2M):
382.38K
Also Trade In:
Volume:
199.23K
At Loss
Avg Vol (2M):
382.38K

Business Description

Description
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.39
Equity-to-Asset -0.45
Debt-to-Equity -1.01
Debt-to-EBITDA -0.39
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -10.87
Distress
Grey
Safe
Beneish M-Score -3.37
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 38.06
9-Day RSI 41.32
14-Day RSI 42.89
6-1 Month Momentum % -70.66
12-1 Month Momentum % -91.79

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.5
Quick Ratio 0.47
Cash Ratio 0.3
Days Inventory 142.59
Days Sales Outstanding 150.64
Days Payable 295.01

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -45.3
Shareholder Yield % -2292.5

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 44.56
Operating Margin % -553.17
Net Margin % -852.8
FCF Margin % -378.42
ROA % -103.91
ROIC % -78.82
ROC (Joel Greenblatt) % -424.7
ROCE % -178.27
Years of Profitability over Past 10-Year 1

Financials (Next Earnings Date:2024-05-15 Est.)

SRNEQ's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:SRNEQ

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Sorrento Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 64.27
EPS (TTM) ($) -1.12
Beta 2.39
Volatility % 216.24
14-Day RSI 42.89
14-Day ATR ($) 0.014455
20-Day SMA ($) 0.015413
12-1 Month Momentum % -91.79
52-Week Range ($) 0.001 - 0.419
Shares Outstanding (Mil) 551.28

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Sorrento Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Sorrento Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Sorrento Therapeutics Inc Frequently Asked Questions

What is Sorrento Therapeutics Inc(SRNEQ)'s stock price today?
The current price of SRNEQ is $0.01. The 52 week high of SRNEQ is $0.42 and 52 week low is $0.00.
When is next earnings date of Sorrento Therapeutics Inc(SRNEQ)?
The next earnings date of Sorrento Therapeutics Inc(SRNEQ) is 2024-05-15 Est..
Does Sorrento Therapeutics Inc(SRNEQ) pay dividends? If so, how much?
Sorrento Therapeutics Inc(SRNEQ) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1